Konference: 2007 ECLU Congress ESMO - účast ČR

Kategorie: Ostatní

Téma: Basic science and bench to bedside

Číslo abstraktu: 006P

Autoři: prof. MUDr. Petra Tesařová, CSc.; MUDr. Jaroslava Barkmanová; Marta Kalousova; Ing. Oto Mestek, CSc.; Zdeňka Dlouhá; prof. MUDr. Tomáš Zima, DrSc., MBA; prof. MUDr. Luboš Petruželka, CSc.

Background: Endothelial activation and/or dysfunction with increased expression of adhesion molecules (E-selectin, P-selectin, ICAM-1) and increased production of prothrombotic (thromboxane A2) and antifibrinolytic (e.g. PAI-1) factors has been demonstrated in patients with advanced cancer and may be the prerequisite for the formation of metastases and neoangiogenesis.Currently it is unclear if the patients with cancer present only with endothelial activation, or if the changes of endothelial
function in cancer can be characterized similarly as in atherosclerosis as a generalised endothelial dysfunction and if the signs of endothelial activation are present already in patients with non-metastatic breast cancer.

Methods: We examined soluble(s) P-selectin, E-selectin, ICAM-1 and VEGF,coagulation parameters and flow-mediated vasodilation and their relation to TNM classification, size of the tumor, its grade, expression of estrogen and progesterone and Her/neu receptors and the clinical outcome in 57 patients with breast cancer.

Preliminary results: plasma levels of sE-selectin, but not sP-selectin, sICAM-1 and VEGF correlated with the size of the tumour (median levels 43.2 vs. 77.4 vs. 95.5 ng/ml in T2, T3 and T4 tumours, respectively, P < 0.05).sE-selectin correlated with sICAM-1 (r = 0.553, P < 0.001) and sP-selectin correlated with VEGF (r = 0.364, P < 0.005). In conclusion, increase of plasma levels of sE-selectin could have been demonstrated not only in patients with metastatic breast cancer, but also in patients with large nonmetastatic tumour. Further studies should delineate if the increase of sE-selectin is also accompanied by other signs of endothelial dysfunction, e.g. impaired flow-mediated vasodilation.

Supported by the grant of IGA of the Ministry of Health of the Czech Republic No.9020-3.

Datum přednesení příspěvku: 5. 7. 2007